Volitionrx

Q2 FY2026 EarningsQ2 FY2026 missed consensus estimates on the top line with revenue of $0.40M vs. $0.47M expected, though GAAP EPS of -$0.85 was wider than the -$0.57 expected due to heavy non-cash debt charges. Product revenue grew 63% YoY driven by Nu.Q® Vet and Discover kits, while operating losses narrowed by 34% YoY following a 32% reduction in operating expenses. Liquidity remains critical with only $2.8M in cash, as management continues to rely on ATM facilities and debt financing to sustain its 'going concern' status.